FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017111571> ?p ?o ?g. }

• W2017111571 endingPage "1708" @default.
• W2017111571 startingPage "1699" @default.
• W2017111571 abstract "BACKGROUND: A study was conducted to determine the 5-year recurrence-free survival in patients with high-risk prostate cancer after neoadjuvant combination chemotherapy followed by surgery. Secondary endpoints included safety, pathologic effects of chemotherapy, and predictors of disease recurrence. METHODS: Fifty-seven patients were enrolled in a phase 1/2 study of weekly docetaxel 35 mg/m2 and escalating mitoxantrone to 4 mg/m2 before prostatectomy. Patients were treated with 16 weeks of chemotherapy administered weekly on a 3 of every 4 week schedule. A tissue microarray, constructed from the prostatectomy specimens, served to facilitate the exploratory evaluation of biomarkers. The primary endpoint was recurrence-free survival. Disease recurrence was defined as a confirmed serum prostate-specific antigen (PSA) >0.4 ng/mL. RESULTS: Of the 57 patients, 54 received 4 cycles of docetaxel and mitoxantrone before radical prostatectomy. Grade 4 toxicities were limited to leukopenia, neutropenia, and hyperglycemia. Serum testosterone levels remained stable after chemotherapy. Negative surgical margins were attained in 67% of cases. Lymph node involvement was detected in 18.5% of cases. With a median follow-up of 63 months, 27 of 57 (47.4%) patients recurred. The Kaplan-Meier recurrence-free survival at 2 years was 65.5% (95% confidence interval [CI], 53.0%-78.0%) and was 49.8% at 5 years (95% CI, 35.5%-64.1%). Pretreatment serum PSA, lymph node involvement, and postchemotherapy tissue vascular endothelial growth factor expression were independent predictors of early recurrence. CONCLUSIONS: Preoperative chemotherapy with docetaxel and mitoxantrone is feasible. Approximately half of the high-risk patients remain free of disease recurrence at 5 years, and clinical and molecular predictors of early recurrence were identified. Cancer 2010. © 2010 American Cancer Society." @default.
• W2017111571 created "2016-06-24" @default.
• W2017111571 creator A5000485593 @default.
• W2017111571 creator A5001591556 @default.
• W2017111571 creator A5007288249 @default.
• W2017111571 creator A5019899178 @default.
• W2017111571 creator A5034110828 @default.
• W2017111571 creator A5048477205 @default.
• W2017111571 creator A5061050783 @default.
• W2017111571 creator A5078273320 @default.
• W2017111571 creator A5078621860 @default.
• W2017111571 date "2010-04-01" @default.
• W2017111571 modified "2023-10-03" @default.
• W2017111571 title "Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer" @default.
• W2017111571 cites W1544742800 @default.
• W2017111571 cites W1547280737 @default.
• W2017111571 cites W1967324977 @default.
• W2017111571 cites W1970316517 @default.
• W2017111571 cites W1975323370 @default.
• W2017111571 cites W1978960711 @default.
• W2017111571 cites W2019425393 @default.
• W2017111571 cites W2025928627 @default.
• W2017111571 cites W2037610329 @default.
• W2017111571 cites W2047302001 @default.
• W2017111571 cites W2062724290 @default.
• W2017111571 cites W2067475417 @default.
• W2017111571 cites W2073298306 @default.
• W2017111571 cites W2078102851 @default.
• W2017111571 cites W2080439368 @default.
• W2017111571 cites W2087274845 @default.
• W2017111571 cites W2120292596 @default.
• W2017111571 cites W2135312889 @default.
• W2017111571 cites W2137491531 @default.
• W2017111571 cites W2140023635 @default.
• W2017111571 cites W2149596437 @default.
• W2017111571 cites W2152561234 @default.
• W2017111571 cites W2156569873 @default.
• W2017111571 cites W3023689102 @default.
• W2017111571 doi "https://doi.org/10.1002/cncr.24960" @default.
• W2017111571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2846994" @default.
• W2017111571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20143429" @default.
• W2017111571 hasPublicationYear "2010" @default.
• W2017111571 type Work @default.
• W2017111571 sameAs 2017111571 @default.
• W2017111571 citedByCount "35" @default.
• W2017111571 countsByYear W20171115712012 @default.
• W2017111571 countsByYear W20171115712013 @default.
• W2017111571 countsByYear W20171115712014 @default.
• W2017111571 countsByYear W20171115712015 @default.
• W2017111571 countsByYear W20171115712016 @default.
• W2017111571 countsByYear W20171115712017 @default.
• W2017111571 countsByYear W20171115712018 @default.
• W2017111571 countsByYear W20171115712020 @default.
• W2017111571 countsByYear W20171115712021 @default.
• W2017111571 countsByYear W20171115712023 @default.
• W2017111571 crossrefType "journal-article" @default.
• W2017111571 hasAuthorship W2017111571A5000485593 @default.
• W2017111571 hasAuthorship W2017111571A5001591556 @default.
• W2017111571 hasAuthorship W2017111571A5007288249 @default.
• W2017111571 hasAuthorship W2017111571A5019899178 @default.
• W2017111571 hasAuthorship W2017111571A5034110828 @default.
• W2017111571 hasAuthorship W2017111571A5048477205 @default.
• W2017111571 hasAuthorship W2017111571A5061050783 @default.
• W2017111571 hasAuthorship W2017111571A5078273320 @default.
• W2017111571 hasAuthorship W2017111571A5078621860 @default.
• W2017111571 hasBestOaLocation W20171115712 @default.
• W2017111571 hasConcept C121608353 @default.
• W2017111571 hasConcept C126322002 @default.
• W2017111571 hasConcept C126894567 @default.
• W2017111571 hasConcept C141071460 @default.
• W2017111571 hasConcept C143998085 @default.
• W2017111571 hasConcept C203092338 @default.
• W2017111571 hasConcept C2776694085 @default.
• W2017111571 hasConcept C2779466945 @default.
• W2017111571 hasConcept C2780192828 @default.
• W2017111571 hasConcept C2780923524 @default.
• W2017111571 hasConcept C2781190966 @default.
• W2017111571 hasConcept C2781406297 @default.
• W2017111571 hasConcept C535046627 @default.
• W2017111571 hasConcept C71924100 @default.
• W2017111571 hasConceptScore W2017111571C121608353 @default.
• W2017111571 hasConceptScore W2017111571C126322002 @default.
• W2017111571 hasConceptScore W2017111571C126894567 @default.
• W2017111571 hasConceptScore W2017111571C141071460 @default.
• W2017111571 hasConceptScore W2017111571C143998085 @default.
• W2017111571 hasConceptScore W2017111571C203092338 @default.
• W2017111571 hasConceptScore W2017111571C2776694085 @default.
• W2017111571 hasConceptScore W2017111571C2779466945 @default.
• W2017111571 hasConceptScore W2017111571C2780192828 @default.
• W2017111571 hasConceptScore W2017111571C2780923524 @default.
• W2017111571 hasConceptScore W2017111571C2781190966 @default.
• W2017111571 hasConceptScore W2017111571C2781406297 @default.
• W2017111571 hasConceptScore W2017111571C535046627 @default.
• W2017111571 hasConceptScore W2017111571C71924100 @default.
• W2017111571 hasIssue "7" @default.
• W2017111571 hasLocation W20171115711 @default.
• W2017111571 hasLocation W20171115712 @default.
• W2017111571 hasLocation W20171115713 @default.

• next